The Gross Margin of Genetix Biotherapeutics Inc (BLUE) is
-6.65%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2024-12-31 |
-6.65%
|
| 2023-12-31 |
-13.66%
|
| 2022-12-31 |
-180.00%
|
| 2021-12-31 |
-961.75%
|
| 2020-12-31 |
97.85%
|
| 2019-12-31 |
93.29%
|
| 2018-12-31 |
98.37%
|
| 2017-12-31 |
95.68%
|
| Ticker |
Name |
Value |
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|
|
CYTK
|
Cytokinetics, Incorporated
|
7775.20%
|
|
IMGN
|
ImmunoGen Inc
|
99.82%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
CGEM
|
Cullinan Therapeutics, Inc.
|
7775.20%
|
|
GBIO
|
Generation Bio Co
|
7775.20%
|
|
BCAB
|
Bioatla Inc
|
7775.20%
|
|
GBT
|
Global Blood Therapeutics Inc
|
98.30%
|
|
MYOV
|
Myovant Sciences Ltd
|
77.68%
|
|
SGMO
|
Sangamo Therapeutics Inc
|
7775.20%
|
|
YMAB
|
Y-mAbs Therapeutics Inc
|
82.89%
|
|
FOLD
|
Amicus Therapeutics Inc
|
88.50%
|
|
INO
|
Inovio Pharmaceuticals Inc
|
60.13%
|
|
KURA
|
Kura Oncology, Inc.
|
99.92%
|
|
OLMA
|
Olema Pharmaceuticals, Inc.
|
7775.20%
|
|
RCUS
|
Arcus Biosciences, Inc.
|
7775.20%
|
|
RGNX
|
REGENXBIO Inc.
|
88.09%
|
|
LGND
|
Ligand Pharmaceuticals Incorporated
|
74.78%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
NRIX
|
Nurix Therapeutics, Inc.
|
7775.20%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
ALEC
|
Alector, Inc.
|
7775.20%
|
|
CCCC
|
C4 Therapeutics, Inc.
|
7775.20%
|
|
MCRB
|
Seres Therapeutics, Inc.
|
7775.20%
|
|
DMTK
|
DermTech Inc
|
1.80%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
IRWD
|
Ironwood Pharmaceuticals, Inc.
|
100.00%
|
|
ZYME
|
Zymeworks Inc.
|
7775.20%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
AMGN
|
Amgen Inc
|
70.78%
|
|
QURE
|
uniQure N.V.
|
89.53%
|